Bone Biologics Q2 net loss widens 4.48% to $773,702 - BBLG News | RalliesBone Biologics Q2 net loss widens 4.48% to $773,702
B
BBLG• Q2 results
- Bone Biologics posted a Q2 net loss of USD 773,702, widening 4.48% from a year earlier.
- Operating loss widened 8.02% to USD 808,106 as total operating expenses rose 8.02% to USD 808,106.
- R&D expense climbed 61.13% to USD 308,747 due to development work to extend protein shelf-life.
- G&A costs fell 10.26% to USD 499,359; interest income more than doubled to USD 34,512.
- Cash totaled USD 4.03 million at June 30, 2026; a July 2026 private placement raised about USD 2.7 million net.
SVRE
•
